drugset / Trial / NCT00856908

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

NCT00856908

Phase 2 Completed 20 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin

Timeline

Start
2009-02
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule Oral